1. Introduction {#s0005}
===============

Recently, a severe and highly contagious viral disease was evolved in Wuhan, China \[[@bb0005]\]. The causative agent was detected to be a new coronavirus and termed as Coronavirus disease 2019 (COVID-19).

Coronavirus has been associated with several infectious epidemics with major health hazard concerns. In 2000--2004, the Severe Acute Respiratory Syndrome CoV (SARS CoV) was evolved \[[@bb0010]\]. The source of the infection was recorded from animal origins, including a bat as an intermediate host \[[@bb0015]\]. About a decade later, the Middle East Respiratory Syndrome Coronavirus (MERS CoV) was diagnosed in Saudi Arabia \[[@bb0020]\]. Soon after the emergence of SARS and MERS CoVs, they spread to outside of the countries of its origin, causing major world-wide concerns \[[@bb0025],[@bb0030]\]. Lastly, COVID-19 emerged in Wuhan, China. The first isolation was related to an animal market and human-to-human transmission was recorded \[[@bb0035]\].

The coronavirus polyprotein encodes two proteases, which share in its processing and release of the translated non-structural proteins (NSPs), the main protease is called 3-C-like protease (M-pro) and a papain-like protease (Plpro) \[[@bb0040]\]. Both Plpro and Mpro were vital targets for drug discovery studies against the recent coronavirus epidemics including SARS and MERS CoV \[[@bb0045], [@bb0050], [@bb0055], [@bb0060]\].

The first and the only available crystal structure of COVID-19 proteins is Mpro, which was published in February 2020 (PDB ID [6lu7](pdb:6lu7){#ir0005}). In this study, the first virtual screening study against the first known COVID-19 was performed. The obtained results will help in the repurposing of already approved drugs to combat the recent dangerous COVID-19.

2. Methods {#s0010}
==========

2.1. Retrieval of Mpro sequences {#s0015}
--------------------------------

The NCBI GenBank or GISAID (<https://www.gisaid.org/>) were used to obtain the COVID-19 sequences. SARS CoV and MERS CoV sequences were obtained from the GenBank.

2.2. Sequence alignment and multiple sequence comparisons {#s0020}
---------------------------------------------------------

Pairwise and multiple sequence comparisons of Mpro were done using CLC genomics software (Qiagen Inc., USA). The sequence comparison matrix was generated, including the number of gaps, number of different residues and identity %.

2.3. Construction of phylogenetic tree {#s0025}
--------------------------------------

The aligned sequences file was used to generate, a phylogenetic tree by using the neighbor joining method implemented in CLC genomics workbench software.

2.4. Construction of drugs dataset and ligand preparation {#s0030}
---------------------------------------------------------

FDA approved drugs dataset was retrieved from Selleckchem Inc. (WA, USA). All compounds were imported to Ligprep software, deslated and 3D optimized using OPLS2005 force field.

2.5. COVID-19 Mpro protein preparation {#s0035}
--------------------------------------

Virtual screening was implemented by using the published crystal structure of COVID-19 Mpro (PDB ID [6lu7](pdb:6lu7){#ir0015}). The protein preparation module in Maestro software package (Schrodinger LLC, NY, USA) was used to optimize the protein structure for docking. Water and other nonspecific molecules were removed, the protein was protonated to add polar hydrogens, the structure was optimized at cellular pH conditions, and the structure energy minimized using OPLS2005 force field. The docking grid was generated by using the co-crystalised ligand as the center for docking box of 20 Å size.

2.6. Virtual screening {#s0040}
----------------------

The Schrodinger glide docking module was used for virtual screening. In order to get accurate results, the standard precision (SP docking) was selected \[[@bb9000],[@bb8000]\]. The output results were ordered by docking score. In this set, the curcumin was found to be a strong inhibitor of SARS Mpro \[[@bb0065]\]. The measured IC50 was 0.0235 μM. The obtained docking results were reanalyzed to include a comparison with curcumin. The relative docking scores were calculated for every compound by dividing its score with the docking score curcumin.

3. Results and discussion {#s0045}
=========================

Molecular modeling, virtual screening and other computational techniques are widely used methods to understand the phylogenetics, molecular aspects of proteins and protein-ligand interactions during drug discovery process \[[@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090]\]. Virtual screening has been used in drug discovery against emerging and fatal diseases including SARS CoV proteases \[[@bb0095],[@bb0100]\], Hepatitis C virus RNA-dependent RNA polymerase \[[@bb0105]\], dengue virus \[[@bb0110]\] and Ebola virus \[[@bb0115]\].

In this work, we cover a knowledge gap about the COVID-19 Mpro and its comparison with the two most dangerous coronavirus epidemics, SARS and MERS CoVs. In addition, we used the first resolved COVID-19 crystal structure of Mpro to find suitable binding agents with proved safety. In this context, the FDA approved drugs were the best starting point in the way of repurposing approved and safe drugs against COVID-19.

At first, the Mpro from COVID-19 was compared with SARS and MERS CoVs ([Fig. 1](#f0005){ref-type="fig"} ). Comparing COVID-19 Mpro with SARS Mpro ([Fig. 1](#f0005){ref-type="fig"}A) and MERS CoV Mpro ([Fig. 1](#f0005){ref-type="fig"}B) revealed high degree of conservation between COVID-19 and SARS CoV Mpros and little number of different residues. However, MERS CoV Mpro showed large number of differences and low conservation with COVID-19 Mpro. This was evidenced by the phylogenetic relations ([Fig. 1](#f0005){ref-type="fig"}C), which showed close relation of SARS and COVID-19 Mpros and distant relation to MERS CoV.Fig. 1Sequences alignment and phylogenetic relations of Mpro from SARS CoV, MERS CoV and COVID-19. A) Pairwise sequence alignment of COVID-19 and SARS CoVs Mpro. Conserved residues are not highlighted and displayed in black colour. The different residues are highlighted in by red colour B) pairwise sequence comparison of COVID-19 and MERS CoVs. Conserved residues are not highlighted and displayed in black colour. The different residues are highlighted in by red colour. C) the phylogenetic relations of Mpro, the tree was generated after the maximum likelihood. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

Statistics of sequences comparison was generated in a pairwise sequence comparison matrix ([Table 1](#t0005){ref-type="table"} ). There was 96.08% identity between COVID-19 and SARS CoV Mpro, while low identity% of 51.61 was detected for COVID-19 and MERS CoV Mpro. The number of COVID-19 amino acid differences was 12 and 153 for SARS CoV and MERS CoV, respectively.Table 1Sequence comparison matrix of COVID-19, SARS and MERS CoVs Mpro. The upper diagonal panel shows the number of amino acids differences. The lower diagonal panel shows the identity%.Table 1COVID-19SARS CoVMERS CoVCOVID-1912150SARS CoV96.08153MERS CoV51.6150.65

The results of virtual screening of FDA approved drugs against COVID-Mpro is presented in [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}. The presented parameters include the docking scores, ligand efficiency, lipophilic and hydrogen bonding interactions. The top 20 hits showing the highest docking score are provided in [Table 2](#t0010){ref-type="table"}. The data were presented as a relative value to curcumin (a previously approved SARS Mpro inhibitor). Curcumin docking score was ranked at the 334 position, implying the presence of wide range of expected more powerful binding drugs. Within the top 20 drugs there was 2 antivirals, 2 antituberculous agents, 2 vitamins, 1 anticancer and other miscellaneous systemically acting drugs.

Among antivirals, ribavirin and telbivudine were ranked at the second and third positions. They showed 2 folds increase in the docking scores, compared with curcumin. Vitamin B12 and nicotinamide were ranked at the 4th and 6th positions.Table 2The top 20 drugs showing the highest docking score.Table 2Item nameFormulaMWRelative docking scoreRelative ligand efficiencyRelative glide lipoRelative glide hbondClinical usesChromocarbC10H6O41902.084.030.924.80VasoprotectiveRibavirinC8H12N4O52442.013.210.374.36AntiviralTelbivudineC10H14N2O52422.003.190.446.12Hepatitis B virusVitamin B12C63H88CoN14O14P13551.990.600.499.70VitaminAminophyllineC16H24N10O44201.924.000.463.20BronchodilatorNicotinamideC6H6N2O1221.915.760.715.76VitaminTriflusalC10H7F3O42481.872.991.052.53CardiovascularBemegrideC8H13NO21551.834.520.683.88CNS stimulantAminosalicylate SodiumC7H6NNaO31751.804.440.761.60Antituberculosis agentsPyrazinamideC5H5N3O1231.805.420.524.29Antituberculosis agentsTemozolomideC6H6N6O21941.793.470.123.20AnticancerMethazolamideC5H8N4O3S22361.783.450.005.76GlaucomaTioxoloneC7H4O3S1681.784.380.923.20Anti-acnePropylthiouracilC7H10N2OS1701.774.380.563.20Antithyroid agentCysteamine HClC2H8ClNS1141.7712.010.002.00Nephropathic cystinosismethoxamine hydrochlorideC11H18ClNO32481.773.200.105.09Alpha-adrenergic agonistZonisamideC8H8N2O3S2121.763.420.473.20Anticonvulsant(+,-)-Octopamine HClC8H12ClNO21901.764.330.095.09Adrenergic agonistAmiloride hydrochlorideC6H9Cl2N7O2661.763.180.306.69Diuretic

Ribavirin is abroad spectrum antiviral agent acting by induction of mutations in the viral genome, especially in RNA viruses \[[@bb0120]\]. Ribavirin is officially approved for treating respiratory syncytial virus (RSV) infection and, in combination with interferon α2b for hepatitis C virus \[[@bb0125]\]. In addition, it was used for treating SARS CoV infections \[[@bb0125]\]. Given the high similarity of SARS and COVID-19 Mpros, ribavirin might be of a value in treating COVID-19.

Telbivudine is approved for treating hepatitis B virus \[[@bb0130]\]. The drug is nucleoside analogue and best fits the viral polymerase. The high rank of telbivudine in this study suggests its repurposing for COVID-19 treatment by its binding to Mpro.

In comparison with curcumin, the top 10 ranked compounds showed improved hydrogen bonding profile. There was 1.6--9.7 fold increase in hydrogen bonding interactions. In contrast, the hydrophobic interactions were kept constant or lowered.

By inspection of the binding mode of top ranked drugs, hydrogen bonding and hydrophobic interactions were the driving force for binding ([Fig. 2](#f0010){ref-type="fig"} ). Ribavirin formed two hydrogen bonds with the backbone of THR25 and side chain of GLN189 ([Fig. 2](#f0010){ref-type="fig"}B and C). Telbivudine formed two hydrogen bonds with SER49 and GLV189 ([Fig. 2](#f0010){ref-type="fig"}D and E).Fig. 2Virtual screening and docking of FDA drugs with COVID-19 Mpro. A) The top 40 compounds docked into the Mpro binding site. B) The docking site of ribavirin C) The ligand interactions of ribavirin with Mpro D) The site of docking of telbivudine E) The ligand interactions of telbivudine with Mpro. Hydrogen bonds are shown in purple arrows, hydrophobic interactions in grey circles. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2

In conclusion, molecular modeling tools were used to compare the Mpro of the recently evolved COVID-19 and the previous two coronavirus epidemics SARS and MERS CoV. COVID-19 Mpro was more phylogenetically related to SARS Mpro. After a virtual screening capmain against COVID-19 Mpro, a set of antivirals, vitamins, antimicrobials, and other systemically acting drugs were more potent binding with COVID-19 Mpro, compared with curcumin (known Mpro inhibitor). The repurposing of ribavirin, telbivudine, vitamin B12 and nicotinamide is suggested.

The following is the supplementary data related to this article.Supplementary Table 1The docking output parameters for FDA approved drugs dataset against SARS-CoV-2 Mpro.Supplementary Table 1
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